Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026)
Cellectis' (CLLS) quarterly Total Non-Current Liabilities came in at $94.8 million in Q1 2026, up 11.08% year-on-year from $85.3 million in Q1 2025, and down 8.05% quarter-over-quarter from $103.1 million in Q4 2025.
Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Cellectis' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $94.8 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 11.08% year-over-year to $94.8 million in Q1 2026; TTM through Mar 2026 was $94.8 million, a 11.08% increase from a year earlier, with the FY2025 full-year figure at $103.1 million, up 19.51% from the prior year.
- Total Non-Current Liabilities retreated to $94.8 million in Q1 2026 per CLLS's latest filing, from $103.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $105.4 million in Q1 2024 and bottomed at $70.4 million in Q1 2023.
- The 5-year median for Total Non-Current Liabilities is $89.6 million (2023), against an average of $90.1 million.
- Biggest YoY gain for Total Non-Current Liabilities was 10184.24% in 2022; the steepest drop was 24.91% in 2022.
- Year by year, Total Non-Current Liabilities stood at $72.3 million in 2022, then soared by 30.65% to $94.4 million in 2023, then dropped by 8.67% to $86.2 million in 2024, then increased by 19.51% to $103.1 million in 2025, then fell by 8.05% to $94.8 million in 2026.
- Per Business Quant, the three latest CLLS Total Non-Current Liabilities figures stand at $94.8 million (Q1 2026), $103.1 million (Q4 2025), and $94.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | 94.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.77 Mn |
| Dec 31, 2025 | 103.07 Mn |
| Sep 30, 2025 | 93.99 Mn |
| Jun 30, 2025 | 89.42 Mn |
| Mar 31, 2025 | 85.31 Mn |
| Dec 31, 2024 | 86.24 Mn |
| Sep 30, 2024 | 100.80 Mn |
| Jun 30, 2024 | 98.90 Mn |
| Mar 31, 2024 | 105.45 Mn |
| Dec 31, 2023 | 94.43 Mn |
| Sep 30, 2023 | 89.63 Mn |
| Jun 30, 2023 | 89.07 Mn |
| Mar 31, 2023 | 70.45 Mn |
| Dec 31, 2022 | 72.28 Mn |
| Sep 30, 2022 | 80.94 Mn |
| Jun 30, 2022 | 85.08 Mn |
| Mar 31, 2022 | 91.80 Mn |
| Dec 31, 2021 | 96.25 Mn |
| Sep 30, 2021 | 787,000.00 |
| Jun 30, 2021 | 103.80 Mn |